MedTrace Logo

An Open Label Extension Study of the Efficacy of MORAb-003

NCT01018563 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-12-08

Study results available
· View outcomes & findings →

Summary

An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

MORAb-003

Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Principal Investigators

  • Susan Weil, MD · Morphotek

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-13
Primary Completion
2013-03-05
Completion
2013-03-05

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018563 on ClinicalTrials.gov